University of Surrey   Report issue

Academic/Hospital Phase 1 Phase 3
Founded: Surrey United Kingdom (1966)

Organization Overview

First Clinical Trial
2014
NCT04033796
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Lecturer, Department of Nutritional Sciences, University of Surrey | University of Surrey | University of Surrey, Department of Clinical and Experimental Medicine

Active Ingredients

Drugs in Phase 3 Trials (1)

avelumab (bavencio) (1 trial)

Drugs in Phase 1 Trials (1)

edp1066 (1 trial)

Drugs in Other Trials (6)

alpha-galacto-oligosaccharides (1 trial)

black currant (1 trial)

cocoa flavanols (2 trials)

galactooligosaccharide (1 trial)

maltodextrin (1 trial)

vitamin d3 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colonic Neoplasms (Phase 3)

Dermatitis (Phase 1)

Dermatitis, Atopic (Phase 1)

Eczema (Phase 1)

Microsatellite Instability (Phase 3)

Psoriasis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 8